Novavax Inc. experienced a significant downturn in its stock value, plummeting as much as 24% following a regulatory hold imposed by U.S. authorities on the company’s experimental vaccines that combine influenza and Covid-19. This decision came after a report of a serious nerve disorder in a volunteer who had participated in a study involving the...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
